ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingANIP
ANIP▲2
ANI Pharmaceuticals Q2 Earnings Call: Top 5 Analyst Questions
ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million and growing 25.9% year over year, while adjusted EPS of $2.21 also topped expectations of $2.04. The company reconfirmed full-year revenue guidance of $1.11 billion at the midpoint and reiterated adjusted EPS guidance of $9.44 at the midpoint. During the earnings call, analysts focused on the ramp of Cortrophin Gel, with CEO Nikhil Lalwani noting that July represented the highest month for new cases initiated and that insurance reverification issues were no longer a factor in Q2. Management attributed a lowered Cortrophin guidance to first-half performance rather than deteriorating trends, and highlighted strong leading indicators from the expanded sales force. The company's market capitalization stands at $1.60 billion, with shares trading at $74.77 after the earnings release.
ANI Pharmaceuticals Leads Q2 Revenue Growth But Guides Weakest
ANI Pharmaceuticals reported second-quarter revenues of $266 million, up 25.9% year on year, beating analysts' expectations by 2.4%, but its full-year revenue guidance slightly missed estimates, making it the weakest guidance update among the four generic pharmaceuticals stocks tracked. The group as a whole beat consensus revenue estimates by 2.6%, with Amphastar Pharmaceuticals posting revenues of $183.9 million, up 5.4% year on year and beating expectations by 2%, while Viatris reported revenues of $3.76 billion, up 4.9% year on year and exceeding expectations by 2.2%, and Amneal reported revenues of $796.2 million, up 9.9% year on year and beating expectations by 3.6%. Despite the strong revenue performance, share prices of the four companies have fallen an average of 5.6% since their latest earnings results, with ANI Pharmaceuticals down 9.1% to $75.12, Viatris down 7.6% to $16.32, Amneal down 8.3% to $17.52, and Amphastar up 2.3% to $20.28.
ANI Pharmaceuticals Reports Record Q2 2026 Revenue of $266 Million, Up 26%
ANI Pharmaceuticals reported record second-quarter 2026 revenues of $266 million, a 26% year-over-year increase, driven by strong performance in rare disease and generics. Record Cortrophin Gel revenues reached $117.1 million, up 43% year-over-year and 56% sequentially, while the generics business delivered $99.1 million, up 10% year-over-year. Adjusted EBITDA hit a record $71.6 million, up 32% year-over-year, and the company reaffirmed full-year 2026 guidance for total revenue of $1.08 billion to $1.14 billion and adjusted EBITDA of $285 million to $300 million. Cortrophin Gel full-year guidance was modestly revised to $520 million to $540 million, reflecting first-half results, though back-half expectations remain largely intact. The company completed a 50% expansion of its rare disease sales force to approximately 180 representatives, with strong early demand from the gout launch, as over 95% of new reps generated multiple new cases.
ANI Pharmaceuticals Reports Positive Phase 4 Data for ILUVIEN in Chronic NIU-PS
ANI Pharmaceuticals reported positive topline results from its Phase 4 SYNCHRONICITY trial of the Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis affecting the posterior segment, with both 6-month co-primary endpoints in visual acuity and retinal thickness met in 108 U.S. patients. The data reinforce the expanded ILUVIEN label by showing clinically meaningful inflammatory control in a real-world, predominantly older patient population with complex ocular histories. The upcoming Q2 2026 earnings release on August 7 is seen as the first real opportunity for management to frame how the expanded label and supportive Phase 4 data fit into revenue expectations and margin mix. ANI Pharmaceuticals' narrative projects $1.4 billion revenue and $279.0 million earnings by 2029, requiring 14.1% yearly revenue growth and a $195.1 million earnings increase from $83.9 million today. The most optimistic analysts already expected about $1.2 billion in revenue and roughly $99 million in earnings, and this new data could either reinforce that upbeat view or prompt questions about future growth dependence on a small group of key drugs.
ANI Pharmaceuticals Shows Strong Revenue Growth but Past Profitability Concerns Linger
ANI Pharmaceuticals has posted a 34.1% compounded annual sales growth rate over the past five years, yet its stock has slipped 3.5% since January 2026 while the S&P 500 gained 7.9%. The company’s return on invested capital has improved recently, but its five-year average ROIC remains negative 2%, indicating past growth initiatives lost money. With shares trading at 8.4 times forward earnings, or $78.49, the stock presents a mixed picture of strong momentum and historical capital inefficiency.
ANI Pharmaceuticals to appeal Delaware court ruling denying new trial in CG Oncology dispute
ANI Pharmaceuticals announced it will appeal to the Delaware Supreme Court after a trial court denied its motions for a new trial and judgment as a matter of law in its dispute with CG Oncology. The company is seeking to recover the value of assets it sold to CG Oncology under a 2010 agreement, including a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec. Judge Sheldon K. Rennie issued the denial on July 16, 2026. President and CEO Nikhil Lalwani stated the company respectfully disagrees with the decision and intends to vigorously pursue its legal rights.
ANI Pharma Reports Positive Phase 4 Data for Fluocinolone Acetonide Implant in Chronic Uveitis
ANI Pharmaceuticals reported positive topline results from its Phase 4 SYNCHRONICITY study evaluating a fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye. The two-year study met both co-primary endpoints, showing statistically significant improvements in best corrected visual acuity and central subfield thickness at six months in the intent-to-treat population of 108 patients. Patients achieved a mean improvement of 3.6 letters in best corrected visual acuity from baseline, while mean central subfield thickness decreased by 157.5 microns. The implant is designed to provide continuous low-dose corticosteroid delivery for patients who have previously responded to steroid therapy. The most common adverse events were consistent with prior trials of the implant.
ANI Pharmaceuticals CFO Stephen Carey sold $285,000 in stock after a 32% run
ANI Pharmaceuticals Chief Financial Officer Stephen Carey sold 3,313 shares of common stock on July 2, 2026, for a total transaction value of about $285,000. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2026, involving the exercise of 3,313 options at $49.51 per share and an immediate open-market sale at a weighted-average price of $86.00. The disposition represented just 2% of Carey's direct equity holdings, leaving him with 177,543 directly held shares valued at approximately $15.27 million based on the market close. At the time of the transaction, ANI Pharmaceuticals had a market capitalization of $2.0 billion and the stock had delivered a one-year total return of 32%.
Wall Street sees upside in Alphabet, ANI Pharmaceuticals, and California Resources
Wall Street analysts are bullish on Alphabet, ANI Pharmaceuticals, and California Resources, with consensus price targets implying significant upside. Alphabet, trading at $359.49, has a consensus target of $432.83, suggesting a 20.4% return, driven by strong revenue growth and expanding margins in its core search business, Google Cloud, and YouTube. ANI Pharmaceuticals, at $86.03, has a target of $109.88, implying a 27.7% return, supported by 33.6% annual revenue growth and a sharp increase in free cash flow margin. California Resources, at $51.26, has a target of $82.45, implying a 60.9% return, backed by 17.3% annual revenue growth and a 57.2% gross margin.